Skip to content

Psilocybin: all studies

Page 279 of 440: studies 2,781 to 2,790 of 4,392, newest first. Back to the psilocybin overview

Research

Psychedelics and Mental Health: A Population Study

PLoS One August 19, 2013 Teri Suzanne Krebs, Pål-ørjan Johansen 338 citations

BACKGROUND: The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or...

Serotonergic hallucinogens as translational models relevant to schizophrenia

The International Journal of Neuropsychopharmacology August 13, 2013 Adam L. Halberstadt, Mark A. Geyer 66 citations

Abstract One of the oldest models of schizophrenia is based on the effects of serotonergic hallucinogens such as mescaline, psilocybin, and (+)-lysergic acid diethylamide (LSD), which act through the serotonin 5-HT2A receptor. These compounds produce a ‘model psychosis’ in normal individuals that resembles at least some of the positive symptoms of schizophrenia. Based on these similarities, and...

PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS

Journal of Neurology, Neurosurgery, and Psychiatry August 6, 2013 R. Carhart-Harris 17 citations

After completing an undergraduate degree in Psychology in 2003, Robin studied psychoanalysis at Masters level, receiving his MA in 2004. In 2005, Robin began a four year PhD in Psychopharmacology at the University of Bristol. Working for Professor David Nutt and Dr Sue Wilson, Robin9s thesis focused on sleep and serotonin function in ecstasy users. Robin conducted a clinical study involving...

Neuropsychedelia: the revival of hallucinogen research since the decade of the brain

Choice Reviews Online July 23, 2013 74 citations

Acknowledgments Introduction: Neuropsychopharmacology as Spiritual Technology 1. Psychedelic Revival 2. Swiss Psilocybin and US Dollars 3. The Varieties of Psychedelic Lab Experience 4. Enacting Experimental Psychoses 5. Between Animality and Divinity 6. Mystic Materialism Conclusion: Fieldwork in Perennial Philosophy Notes Bibliography Index

Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

Journal of Psychopharmacology June 19, 2013 Rl Carhart-Harris, Stefan Brugger, Dj Nutt et al. 43 citations

Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the effects of five drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) in relation to psychiatric symptoms in a two-part subjective analysis. In the first part, mental health professionals...

Preclinical models of antipsychotic drug action

The International Journal of Neuropsychopharmacology June 10, 2013 José L. Moreno, Javier González-Maeso 30 citations

Abstract One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders. Behavioural pharmacology studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those observed...

Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice

Neuroscience Letters January 16, 2013 José L. Moreno, Terrell Holloway, Vinayak Rayannavar et al. 44 citations

Hallucinogenic drugs, such as lysergic acid diethylamide (LSD), mescaline and psilocybin, alter perception and cognitive processes. All hallucinogenic drugs have in common a high affinity for the serotonin 5-HT(2A) receptor. Metabotropic glutamate 2/3 (mGlu2/3) receptor ligands show efficacy in modulating the cellular and behavioral responses induced by hallucinogenic drugs. Here, we explored...

Literature review: Considerations for Psychedelic Research

UC Merced Undergraduate Research Journal 2013 Charlesice Hawkins

Research on psychedelic substances is re-emerging. Here we review chemical and physiological effects in addition to medical uses for psychedelic substances. The most common substances included here as psychedelics are lysergic acid diethylamide (LSD), psilocybin, and peyote. Safety is the priority underlying the majority of the following studies.

"Magic" mushrooms don't cause renal failure

BMJ October 17, 2012 Edward G. D. Tuddenham

“We have had recent experience with renal toxicity caused by deliberate ingestion of psilocybin mushrooms, which are eaten for their hallucinogenic effects. Acute renal failure secondary to the recreational use of mushrooms is rarely reported.”1 Each of these statements is problematic. The authors give no …

DOI: 10.1136/bmj.e6893 (opens in new tab) Psilocybin Hallucinogen Magic telescope Recreational drug +5

Animal Models of Serotonergic Psychedelics

ACS Chemical Neuroscience September 24, 2012 James B. Hanks, Javier González-Maeso 152 citations

The serotonin 5-HT(2A) receptor is the major target of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Serotonergic psychedelics induce profound effects on cognition, emotion, and sensory processing that often seem uniquely human. This raises questions about the validity of animal models of psychedelic drug action. Nonetheless, recent findings suggest...